Actualités
Dengue Virus dependence on glucokinase activity and glycolysis Confers Sensitivity to NAD(H) biosynthesis inhibitors
Ogire E, Perrin-Cocon L, Figl M, Kundlacz C, Jacquemin C, Hubert S, Aublin-Gex A, Toesca J, Ramière C, Vidalain PO, Mathieu C, Lotteau V, Diaz O. Antiviral Res. 2024 Jun 22;228:105939. DOI: 10.1016/j.antiviral.2024.105939
Tethering of hexokinase 2 to mitochondria promotes resistance of liver cancer cells to natural killer cell cytotoxicity
Aublin-Gex A, Jacolin F, Diaz O, Jacquemin C, Marçais A, Walzer T, Lotteau V, Vidalain PO, Perrin-Cocon L. Eur J Immunol. 2024 Jun 4:e2350954. doi: 10.1002/eji.202350954.
NDP52 mediates an antiviral response to hepatitis B virus infection through Rab9-dependent lysosomal degradation pathway
Cui S, Xia T, Zhao J, Ren X, Wu T, Kameni M, Guo X, He L, Guo J, Duperray-Susini A, Levillayer F, Collard JM, Zhong J, Pan L, Tangy F, Vidalain PO, Zhou D, Jiu Y, Faure M, Wei Y. Nat Commun. 2023 Dec 19;14(1):8440. doi: 10.1038/s41467-023-44201-2. PMID: 38114531
Rôle du métabolisme cellulaire dans le contrôle des hépatites virales chroniques
Olivier Diaz, Anne-Flore Legrand*, Walid El-Orch*, Florentine Jacolin*, Vincent Lotteau, Christophe Ramière, Pierre-Olivier Vidalain & Laure Perrin-Cocon. Med Sci (Paris). 2023 Oct;39(10):754-762. doi: 10.1051/medsci/2023125. French.
Farnesoid X receptor alpha ligands inhibit HDV in vitro replication and virion infectivity.
Legrand AF, Lucifora J, Lacombe B, Ménard C, Michelet M, Foca A, Abrial P, Salvetti A, Rivoire M, Lotteau V, Durantel D, André P, Ramière C. Hepatol Commun. 2023 Apr 14;7(5):e0078.
An inventory of adjuvants used for vaccination in horses: the past, the present and the future.
Carnet F, Perrin-Cocon L, Paillot R, Lotteau V, Pronost S, Vidalain PO. Vet Res. 2023 Mar 2;54(1):18. doi: 10.1186/s13567-023-01151-3.
What role for cellular metabolism in the control of hepatitis viruses?
Olivier Diaz, Pierre-Olivier Vidalain, Christophe Ramière, Vincent Lotteau and Laure Perrin-Cocon. Front. Immunol. 13:1033314.
A hexokinase isoenzyme switch in human liver cancer cells promotes lipogenesis and enhances innate immunity
During liver carcinogenesis, the first enzyme of glycolysis GCK is replaced in hepatocytes by the hexokinase HK2. We show that it critically contributes to metabolic reprogramming and inhibition of innate immunity associated to liver cancer development.